NextCell Pharma AB
STO:NXTCL
NextCell Pharma AB
Other
NextCell Pharma AB
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NextCell Pharma AB
STO:NXTCL
|
Other
-kr1.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other
-kr5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other
-kr49.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other
-kr10m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other
kr555m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Other
kr26.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NextCell Pharma AB
Glance View
NextCell Pharma AB engages in the development of stem cell products. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2017-07-13. The firm is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
See Also
What is NextCell Pharma AB's Other?
Other
-1.5m
SEK
Based on the financial report for Aug 31, 2025, NextCell Pharma AB's Other amounts to -1.5m SEK.
What is NextCell Pharma AB's Other growth rate?
Other CAGR 1Y
72%
Over the last year, the Other growth was 72%.
